Clinical Trial Update: Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

View source ↗

Summary

This completed trial investigates eosinophil β1 integrin activation as a biomarker for eosinophilic esophagitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Eosinophilic Esophagitis | Status: COMPLETED